BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 36216198)

  • 1. Inhibition on XBP1s-driven lipogenesis by Qushi Huayu Decoction contributes to amelioration of hepatic steatosis induced by fructose.
    Tian H; Fang Y; Liu W; Wang J; Zhao J; Tang H; Yin Y; Hu Y; Peng J
    J Ethnopharmacol; 2023 Jan; 301():115806. PubMed ID: 36216198
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tcf7l2 in hepatocytes regulates de novo lipogenesis in diet-induced non-alcoholic fatty liver disease in mice.
    Lee DS; An TH; Kim H; Jung E; Kim G; Oh SY; Kim JS; Chun HJ; Jung J; Lee EW; Han BS; Han DH; Lee YH; Han TS; Hur K; Lee CH; Kim DS; Kim WK; Park JW; Koo SH; Seong JK; Lee SC; Kim H; Bae KH; Oh KJ
    Diabetologia; 2023 May; 66(5):931-954. PubMed ID: 36759348
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatocyte leukotriene B4 receptor 1 promotes NAFLD development in obesity.
    Liu X; Wang K; Wang L; Kong L; Hou S; Wan Y; Ma C; Chen J; Xing X; Xing C; Jiang Q; Zhao Q; Cui B; Huang Z; Li P
    Hepatology; 2023 Aug; 78(2):562-577. PubMed ID: 35931467
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Qushi Huayu Decoction Inhibits Hepatic Lipid Accumulation by Activating AMP-Activated Protein Kinase In Vivo and In Vitro.
    Feng Q; Gou XJ; Meng SX; Huang C; Zhang YQ; Tang YJ; Wang WJ; Xu L; Peng JH; Hu YY
    Evid Based Complement Alternat Med; 2013; 2013():184358. PubMed ID: 23573117
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Qushi Huayu decoction attenuated hepatic lipid accumulation via JAK2/STAT3/CPT-1A-related fatty acid β-oxidation in mice with non-alcoholic steatohepatitis.
    Sun Q; Wang X; Xin X; An Z; Hu Y; Feng Q
    Pharm Biol; 2022 Dec; 60(1):2124-2133. PubMed ID: 36308318
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Amelioration of non-alcoholic steatohepatitis by Qushi Huayu decoction is associated with inhibition of the intestinal mitogen-activated protein kinase pathway.
    Leng J; Huang F; Hai Y; Tian H; Liu W; Fang Y; Hu Y; Peng J
    Phytomedicine; 2020 Jan; 66():153135. PubMed ID: 31790895
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Qushi Huayu decoction ameliorates non-alcoholic fatty liver disease in rats by modulating gut microbiota and serum lipids.
    Ni Y; Wang X; Wu Q; Yao Y; Xu Y; Li Y; Feng Q; Zhou M; Gou X
    Front Endocrinol (Lausanne); 2023; 14():1272214. PubMed ID: 37900123
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of Dietary Fructose and Hepatic De Novo Lipogenesis in Fatty Liver Disease.
    Softic S; Cohen DE; Kahn CR
    Dig Dis Sci; 2016 May; 61(5):1282-93. PubMed ID: 26856717
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multi-targeting therapeutic mechanisms of the Chinese herbal medicine QHD in the treatment of non-alcoholic fatty liver disease.
    Feng Q; Liu W; Baker SS; Li H; Chen C; Liu Q; Tang S; Guan L; Tsompana M; Kozielski R; Baker RD; Peng J; Liu P; Zhu R; Hu Y; Zhu L
    Oncotarget; 2017 Apr; 8(17):27820-27838. PubMed ID: 28416740
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment with myo-inositol attenuates binding of the carbohydrate-responsive element-binding protein to the ChREBP-β and FASN genes in rat nonalcoholic fatty liver induced by high-fructose diet.
    Shimada M; Ichigo Y; Shirouchi B; Takashima S; Inagaki M; Nakagawa T; Hayakawa T
    Nutr Res; 2019 Apr; 64():49-55. PubMed ID: 30802722
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD36 promotes de novo lipogenesis in hepatocytes through INSIG2-dependent SREBP1 processing.
    Zeng H; Qin H; Liao M; Zheng E; Luo X; Xiao A; Li Y; Chen L; Wei L; Zhao L; Ruan XZ; Yang P; Chen Y
    Mol Metab; 2022 Mar; 57():101428. PubMed ID: 34974159
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The chloroform extract of Cyclocarya paliurus attenuates high-fat diet induced non-alcoholic hepatic steatosis in Sprague Dawley rats.
    Lin Z; Wu ZF; Jiang CH; Zhang QW; Ouyang S; Che CT; Zhang J; Yin ZQ
    Phytomedicine; 2016 Nov; 23(12):1475-1483. PubMed ID: 27765368
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of X-Box Binding Protein-1 in Fructose-Induced
    Yu X; Ren LP; Wang C; Zhu YJ; Xing HY; Zhao J; Song GY
    Chin Med J (Engl); 2018 Oct; 131(19):2310-2319. PubMed ID: 30246717
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The role of adiponectin and adiponectin receptor 2 in the pathology of fatty liver].
    Li HS; Feng Q; Hu YY; Chen SD; Peng JH; Li XM; Xu LL
    Zhonghua Gan Zang Bing Za Zhi; 2009 Nov; 17(11):826-30. PubMed ID: 19958641
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Naringin attenuates fructose-induced NAFLD progression in rats through reducing endogenous triglyceride synthesis and activating the Nrf2/HO-1 pathway.
    Pengnet S; Sumarithum P; Phongnu N; Prommaouan S; Kantip N; Phoungpetchara I; Malakul W
    Front Pharmacol; 2022; 13():1049818. PubMed ID: 36588703
    [No Abstract]   [Full Text] [Related]  

  • 16. Lycopus lucidus Turcz. ex Benth. Attenuates free fatty acid-induced steatosis in HepG2 cells and non-alcoholic fatty liver disease in high-fat diet-induced obese mice.
    Lee MR; Yang HJ; Park KI; Ma JY
    Phytomedicine; 2019 Mar; 55():14-22. PubMed ID: 30668424
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of fatty acid synthase with FT-4101 safely reduces hepatic de novo lipogenesis and steatosis in obese subjects with non-alcoholic fatty liver disease: Results from two early-phase randomized trials.
    Beysen C; Schroeder P; Wu E; Brevard J; Ribadeneira M; Lu W; Dole K; O'Reilly T; Morrow L; Hompesch M; Hellerstein MK; Li K; Johansson L; Kelly PF
    Diabetes Obes Metab; 2021 Mar; 23(3):700-710. PubMed ID: 33289350
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fructose Consumption, Lipogenesis, and Non-Alcoholic Fatty Liver Disease.
    Ter Horst KW; Serlie MJ
    Nutrients; 2017 Sep; 9(9):. PubMed ID: 28878197
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quercetin ameliorates HFD-induced NAFLD by promoting hepatic VLDL assembly and lipophagy via the IRE1a/XBP1s pathway.
    Zhu X; Xiong T; Liu P; Guo X; Xiao L; Zhou F; Tang Y; Yao P
    Food Chem Toxicol; 2018 Apr; 114():52-60. PubMed ID: 29438776
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The traditional Chinese formulae Ling-gui-zhu-gan decoction alleviated non-alcoholic fatty liver disease via inhibiting PPP1R3C mediated molecules.
    Dang Y; Hao S; Zhou W; Zhang L; Ji G
    BMC Complement Altern Med; 2019 Jan; 19(1):8. PubMed ID: 30616587
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.